Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

FDA grants Breakthrough Therapy status to ION582 based on strong Phase 1/2 results in Angelman syndrome. Phase 3 REVEAL study targeting Angelman syndrome patients is set to enroll until 2026. Get the strategy to turn September's volatility into 10x trades → On Tuesday, the U.S.

Ionis Pharmaceuticals Inc. IONS closed regular trading at $42.81, up 0.78% for the day, before gaining an additional 2.38% in premarket trading to $43.83, according to Benzinga Pro data, following disclosure of insider trading activity by its chief scientific officer.